By Adriano Marchese
Lexeo Therapeutics said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results.
The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug.
The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease.
"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression," the company said.
The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers.
"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology," said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study.
The data were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid, Spain.
Lexeo said it contacted the Food and Drug Administration with the data it has collected. It expects to provide regulatory updates and any new development plans for the drug in 2025.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 30, 2024 07:26 ET (11:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。